Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...

A joint research team affiliated with UNIST has developed a 3D-printed artificial tumor tissue capable of replicating the in ...

Researchers have created a groundbreaking 3D-printed artificial tumor tissue capable of replicating the in vivo conditions of ...

Abstract Heterogeneity and the absence of a tumor microenvironment (TME) in traditional patient-derived organoid (PDO) cultures limit their ...

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatelli ...

Metastatic colorectal cancer (mCRC) continues to pose a clinical and commercial challenge, with low 5-year survival rates and limited durable respons ...

CytomX Therapeutics reveals promising CX-2501 results & strengthens finances with $100M offering. Key updates on cancer ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923,076 shares of ...